Fig. 5: Effects of EBV serostatus on autoantigen specific CD8+ T cells.
From: Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes
A Bubble plot showing the Z score and p values of the pathways with significant differences in the T1D specific CD8+ T cells at the baseline (n = 4 placebo, (EBV-seropositive=2 and EBV-seronegative=2), n = 6 teplizumab, (EBV-seropositive =4, EBV-seronegative =2)) (B) Bubble plot showing the Z score and p values at 18 months in the teplizumab group (n = 3 EBV-seropositive, n = 3 EBV-seronegative). The pathways were determined by IPA analysis based on the DEGs between EBV positive and EBV negative in the T1D specific CD8+ T cells of the teplizumab group filtering out the genes that also show a change at the baseline. Blue scale denotes grades of prediction of downregulation of the pathways based on the Z score. C Volcano plot visualization of the DEGs in the T1D specific CD8+ T cells between EBV-seropositive vs seronegative at eighteen months in the teplizumab group (n = 3 EBV-seropositive and n = 3 EBV-seronegative).Volcano plot visualization of the DEGs in EBV positive vs negative related to the TCR signaling pathway (D) and TNF signaling (E) in the T1D specific CD8+ T cells at 18 months.
